On July 20, 2016 Abbott (NYSE: ABT) reported financial results for the second quarter ended June 30, 2016 (Press release, Abbott, JUL 20, 2016, View Source [SID:1234513964]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Second-quarter worldwide sales of $5.3 billion increased 3.2 percent on a reported basis and 6.4 percent on an operational basis.
Reported diluted EPS from continuing operations under GAAP was $0.40 in the second quarter. Excluding specified items, adjusted diluted EPS from continuing operations was $0.55 in the second quarter, above the previous guidance range.
Abbott’s full-year 2016 EPS for continuing operations under GAAP is projected to be $1.26 to $1.36. Projected full-year 2016 adjusted EPS for continuing operations remains unchanged at $2.14 to $2.24.
In July, Abbott received U.S. FDA approval for AbsorbTM, the only fully dissolving heart stent, as well as U.S. FDA approval for TECNIS Symfony intraocular lenses for the treatment of cataracts, the first and only extended depth of focus lenses for people with cataracts.
In the second quarter, Abbott announced the global launch of AlinIQ, the first-of-its-kind informatics solution with enhanced capabilities to help diagnostics laboratories increase productivity and flexibility in managing data throughout hospital networks.
On April 28, 2016, Abbott announced an agreement to acquire St. Jude Medical, Inc. The transaction will create a premier medical device leader with a highly competitive portfolio that will include an industry-leading pipeline across cardiovascular, neuromodulation, diabetes and vision care.
"It was a good quarter," said Miles D. White, chairman and chief executive officer, Abbott. "We’re particularly pleased with the steady cadence of new product approvals and recent launches that are contributing to growth, including FreeStyle Libre, MitraClip, Absorb and Symfony."
SECOND-QUARTER BUSINESS OVERVIEW
Following are sales by business segment and commentary for the second quarter and first half of the year:
Total Company
($ in millions)
% Change vs. 2Q15
Sales 2Q16
Int’l
Total
U.S.
Int’l
Total
U.S.
Reported
Operational
Reported
Operational
Total *
1,655
3,678
5,333
4.0
2.8
7.5
3.2
6.4
Nutrition
750
990
1,740
3.0
0.2
5.3
1.4
4.3
Diagnostics
361
865
1,226
3.0
4.5
7.3
4.1
6.0
Established Pharmaceuticals
—
980
980
n/a
0.4
9.5
0.4
9.5
Medical Devices
535
837
1,372
6.1
6.6
7.3
6.4
6.8
* Total Abbott Sales from continuing operations include Other Sales of $15 million.
% Change vs. 1H15
Sales 1H16
Int’l
Total
U.S.
Int’l
Total
U.S.
Reported
Operational
Reported
Operational
Total *
3,186
7,032
10,218
3.0
0.8
7.0
1.5
5.8
Nutrition
1,469
1,942
3,411
3.9
(1.5)
4.6
0.8
4.3
Diagnostics
700
1,644
2,344
3.3
3.2
7.7
3.2
6.4
Established Pharmaceuticals
—
1,868
1,868
n/a
(0.3)
10.2
(0.3)
10.2
Medical Devices
1,001
1,568
2,569
1.2
2.8
5.4
2.1
3.7
* Total Abbott Sales from continuing operations include Other Sales of $26 million.
n/a = Not Applicable.
Note: Operational growth reflects percentage change over the prior year excluding the impact of exchange rates. In order to compute results excluding the impact of exchange rates, current year U.S. dollar sales are multiplied or divided, as appropriate, by the current year average foreign exchange rates and then those amounts are multiplied or divided, as appropriate, by the prior year average foreign exchange rates.
Second-quarter 2016 worldwide sales of $5.3 billion increased 3.2 percent on a reported basis, including an unfavorable 3.2 percent effect of foreign exchange, and increased 6.4 percent on an operational basis.
International sales increased 2.8 percent on a reported basis and 7.5 percent on an operational basis in the second quarter. International operational growth was led by strong performance across all of Abbott’s business segments.
Emerging market sales increased 1.1 percent on a reported basis and 8.5 percent on an operational basis in the second quarter. Excluding the impact of Venezuelan operations, emerging market sales would have increased 4.8 percent on a reported basis and 12.4 percent on an operational basis.
Nutrition
($ in millions)
% Change vs. 2Q15
Sales 2Q16
Int’l
Total
U.S.
Int’l
Total
U.S.
Reported
Operational
Reported
Operational
Total
750
990
1,740
3.0
0.2
5.3
1.4
4.3
Pediatric
425
547
972
5.8
(3.4)
1.6
0.4
3.4
Adult
325
443
768
(0.6)
5.1
10.3
2.6
5.5
% Change vs. 1H15
Sales 1H16
Int’l
Total
U.S.
Int’l
Total
U.S.
Reported
Operational
Reported
Operational
Total
1,469
1,942
3,411
3.9
(1.5)
4.6
0.8
4.3
Pediatric
828
1,111
1,939
5.3
(2.8)
2.9
0.5
3.9
Adult
641
831
1,472
2.2
0.3
7.0
1.1
4.9
Worldwide Nutrition sales increased 1.4 percent on a reported basis in the second quarter, including an unfavorable 2.9 percent effect of foreign exchange, and increased 4.3 percent on an operational basis. Excluding the impact of Venezuelan operations, worldwide Nutrition sales would have increased 3.3 percent on a reported basis and 6.2 percent on an operational basis.
Worldwide Pediatric Nutrition sales increased 0.4 percent on a reported basis in the second quarter, including an unfavorable 3.0 percent effect of foreign exchange, and increased 3.4 percent on an operational basis. Sales growth in the quarter was led by above-market growth in the U.S. with continued uptake of recently launched products, including infant and toddler non-GMO products, as well as strong performance across several countries in Latin America and Asia.
Worldwide Adult Nutrition sales increased 2.6 percent on a reported basis in the second quarter, including an unfavorable 2.9 percent effect of foreign exchange, and increased 5.5 percent on an operational basis. Operational sales growth in the quarter was led by strong growth of Abbott’s complete and balanced nutrition brand, Ensure, and double-digit growth internationally.
Diagnostics
($ in millions)
% Change vs. 2Q15
Sales 2Q16
Int’l
Total
U.S.
Int’l
Total
U.S.
Reported
Operational
Reported
Operational
Total
361
865
1,226
3.0
4.5
7.3
4.1
6.0
Core Laboratory
206
772
978
0.1
4.3
7.1
3.4
5.6
Molecular
51
68
119
1.1
3.6
5.9
2.5
3.8
Point of Care
104
25
129
10.2
17.2
17.4
11.5
11.5
% Change vs. 1H15
Sales 1H16
Int’l
Total
U.S.
Int’l
Total
U.S.
Reported
Operational
Reported
Operational
Total
700
1,644
2,344
3.3
3.2
7.7
3.2
6.4
Core Laboratory
396
1,467
1,863
1.2
3.2
7.8
2.8
6.4
Molecular
98
129
227
(0.5)
0.2
4.6
(0.1)
2.4
Point of Care
206
48
254
9.7
12.1
13.4
10.1
10.4
Worldwide Diagnostics sales increased 4.1 percent on a reported basis in the second quarter, including an unfavorable 1.9 percent effect of foreign exchange, and increased 6.0 percent on an operational basis.
Core Laboratory Diagnostics sales increased 3.4 percent on a reported basis in the second quarter, including an unfavorable 2.2 percent effect of foreign exchange, and increased 5.6 percent on an operational basis. Operational sales growth in the quarter was led by double-digit growth in emerging markets. During the quarter, Abbott launched AlinIQ, a first-of-its-kind professional services and informatics solution that enhances diagnostic laboratory productivity and flexibility in managing data throughout hospital networks.
Molecular Diagnostics sales increased 2.5 percent on a reported basis in the second quarter, including an unfavorable 1.3 percent effect of foreign exchange, and increased 3.8 percent on an operational basis. As expected, continued strong growth in Abbott’s infectious disease testing business was partially offset by the planned scale down of its genetics business.
Point of Care Diagnostics sales increased 11.5 percent on a reported and operational basis. Double-digit sales growth was led by continued adoption of Abbott’s i-STAT handheld system in the U.S. and international markets.
Established Pharmaceuticals
($ in millions)
% Change vs. 2Q15
Sales 2Q16
Int’l
Total
U.S.
Int’l
Total
U.S.
Reported
Operational
Reported
Operational
Total
—
980
980
n/a
0.4
9.5
0.4
9.5
Key Emerging Markets
—
754
754
n/a
3.9
15.9
3.9
15.9
Other
—
226
226
n/a
(9.9)
(9.1)
(9.9)
(9.1)
% Change vs. 1H15
Sales 1H16
Int’l
Total
U.S.
Int’l
Total
U.S.
Reported
Operational
Reported
Operational
Total
—
1,868
1,868
n/a
(0.3)
10.2
(0.3)
10.2
Key Emerging Markets
—
1,388
1,388
n/a
0.5
14.0
0.5
14.0
Other
—
480
480
n/a
(2.6)
(0.4)
(2.6)
(0.4)
Established Pharmaceuticals sales increased 0.4 percent on a reported basis in the second quarter, including an unfavorable 9.1 percent effect of foreign exchange, and increased 9.5 percent on an operational basis. Excluding the impact of Venezuelan operations, Established Pharmaceuticals sales would have increased 4.6 percent on a reported basis and 14.1 percent on an operational basis.
Key Emerging Markets include India, Russia, Brazil and China, along with several additional emerging markets that represent the most attractive long-term growth opportunities for Abbott’s branded generics product portfolio. Sales in these key geographies increased 3.9 percent on a reported basis and 15.9 percent on an operational basis. Operational sales growth was led by continued strong growth in India, which comprises more than 20 percent of Abbott’s Established Pharmaceuticals sales, as well as Russia, China and several countries throughout Latin America.
Medical Devices
($ in millions)
% Change vs. 2Q15
Sales 2Q16
Int’l
Total
U.S.
Int’l
Total
U.S.
Reported
Operational
Reported
Operational
Total
535
837
1,372
6.1
6.6
7.3
6.4
6.8
Vascular
346
436
782
16.4
2.7
3.6
8.3
8.9
Diabetes Care
73
210
283
(21.6)
13.4
15.2
1.7
2.8
Medical Optics
116
191
307
1.9
9.1
7.7
6.2
5.4
Vascular Product Lines:
Coronary Devicesa)
202
367
569
3.9
1.2
2.0
2.1
2.6
Endovascularb)
77
68
145
8.5
10.5
12.3
9.4
10.2
a) Includes DES / BVS product portfolio, structural heart, guidewires, balloon catheters and other coronary products.
b) Includes vessel closure, carotid stents and other peripheral products.
% Change vs. 1H15
Sales 1H16
Int’l
Total
U.S.
Int’l
Total
U.S.
Reported
Operational
Reported
Operational
Total
1,001
1,568
2,569
1.2
2.8
5.4
2.1
3.7
Vascular
635
832
1,467
9.3
(0.8)
1.9
3.3
5.0
Diabetes Care
142
384
526
(26.8)
9.3
13.2
(3.6)
(1.1)
Medical Optics
224
352
576
4.5
5.0
6.0
4.8
5.4
Vascular Product Lines:
Coronary Devicesa)
396
703
1,099
4.4
(2.2)
0.4
0.1
1.8
Endovascularb)
150
128
278
9.0
6.8
10.5
7.9
9.7
a) Includes DES / BVS product portfolio, structural heart, guidewires, balloon catheters and other coronary products.
b) Includes vessel closure, carotid stents and other peripheral products.
Worldwide Medical Devices sales increased 6.4 percent on a reported basis in the second quarter, including an unfavorable 0.4 percent effect of foreign exchange, and increased 6.8 percent on an operational basis.
Worldwide sales of Vascular products increased 8.3 percent on a reported basis in the second quarter, including an unfavorable 0.6 percent effect of foreign exchange, and increased 8.9 percent on an operational basis. Sales were favorably impacted by the resolution of previously disputed third-party royalty revenue related to the prior year. Excluding this impact, worldwide sales of Vascular products would have increased 4.1 percent on a reported basis and 4.7 percent on an operational basis, and U.S. sales would have increased 6.2 percent on a reported and operational basis.
Sales growth in Vascular products was led by double-digit growth of MitraClip, Abbott’s device for the treatment of mitral regurgitation, as Abbott continues to build the market for this first-in-class device. Double-digit operational sales growth in Abbott’s Endovascular business was driven by vessel closure products and Supera, Abbott’s unique peripheral stent for the treatment of blockages in the leg. In July, the U.S. FDA approved Abbott’s Absorb bioresorbable stent, the only fully dissolving heart stent. Absorb offers a unique benefit to patients, as it is designed to treat coronary artery disease like a metallic stent, but then disappears after the artery is healed, leaving no metal behind to restrict natural vessel motion.
Worldwide Diabetes Care sales increased 1.7 percent on a reported basis in the second quarter, including an unfavorable 1.1 percent effect of foreign exchange, and increased 2.8 percent on an operational basis. International sales growth was driven by continued consumer uptake of FreeStyle Libre, Abbott’s revolutionary Flash Glucose Monitoring System that eliminates routine finger sticks and finger-stick calibration. In the U.S., sales were impacted by competitive and market dynamics.
Worldwide Medical Optics sales increased 6.2 percent on a reported basis in the second quarter, including a favorable 0.8 percent effect of foreign exchange, and increased 5.4 percent on an operational basis. Operational sales growth was driven by continued market uptake of cataract products in the premium intraocular lens segment. In July, Abbott received U.S. FDA approval for the TECNIS Symfony intraocular lenses, the first and only lenses in the U.S. that provide a full range of continuous high-quality vision following cataract surgery.
ABBOTT’S FULL-YEAR EARNINGS-PER-SHARE GUIDANCE
Abbott projects earnings per share from continuing operations under Generally Accepted Accounting Principles (GAAP) of $1.26 to $1.36 for the full year 2016.
Abbott forecasts net specified items for the full year 2016 of approximately $0.88 per share. Specified items include intangible amortization expense, the impact of the Venezuelan currency devaluation in the first quarter, expenses associated with acquisitions, including bridge facility fees, and charges related to cost reduction initiatives and other expenses, partially offset by the favorable resolution of various tax positions from prior years.
Excluding specified items, projected earnings per share from continuing operations remains unchanged at $2.14 to $2.24 for the full year 2016.
ABBOTT DECLARES 370TH QUARTERLY DIVIDEND
On June 10, 2016, the board of directors of Abbott declared the company’s quarterly dividend of $0.26 per share. Abbott’s cash dividend is payable Aug. 15, 2016, to shareholders of record at the close of business on July 15, 2016.
Abbott is a member of the S&P 500 Dividend Aristocrats Index, which tracks companies that have annually increased their dividend for 25 consecutive years.